NerPharMa S.r.l. – FDA 483
An FDA inspection of NerPharMa S.r.l. in Nerviano, Milan, Italy, revealed significant deficiencies in their manufacturing and laboratory operations. Key issues include inadequate procedures for preventing microbiological contamination of sterile drug products, incomplete and unreliable electronic laboratory records, and a failure to thoroughly investigate unexplained discrepancies and batch rejections. The firm also demonstrated shortcomings in personnel training, environmental monitoring, and instrument calibration procedures.
- Company
- NerPharMa S.r.l.
- Product type
- drugs
ID · e21affab-994e-45dc-be40-f9d8af6d093b
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.